SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR), today announced that results of a microbiologic study on the in vitro activity of OPT-80 and its primary metabolite, OP-1118, have been accepted at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) to be held in Chicago, IL, on September 17-20, 2007. Farah Babakhani, PhD, Biology Group Leader at Optimer, will be presenting the results. Optimer’s medical affairs booth will be located in Hall D in the Lakeside Center at McCormick Place.
